ATE280833T1 - Kationische lipide/dns komplexe zum zielen von genen - Google Patents
Kationische lipide/dns komplexe zum zielen von genenInfo
- Publication number
- ATE280833T1 ATE280833T1 AT96919212T AT96919212T ATE280833T1 AT E280833 T1 ATE280833 T1 AT E280833T1 AT 96919212 T AT96919212 T AT 96919212T AT 96919212 T AT96919212 T AT 96919212T AT E280833 T1 ATE280833 T1 AT E280833T1
- Authority
- AT
- Austria
- Prior art keywords
- cationic lipid
- complexes
- dna complexes
- methods
- genes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/485,005 US5830878A (en) | 1995-06-07 | 1995-06-07 | Cationic lipid: DNA complexes for gene targeting |
| PCT/US1996/009526 WO1996040962A1 (en) | 1995-06-07 | 1996-06-07 | Cationic lipid:dna complexes for gene targeting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE280833T1 true ATE280833T1 (de) | 2004-11-15 |
Family
ID=23926552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96919212T ATE280833T1 (de) | 1995-06-07 | 1996-06-07 | Kationische lipide/dns komplexe zum zielen von genen |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US5830878A (de) |
| EP (1) | EP0832270B1 (de) |
| AT (1) | ATE280833T1 (de) |
| AU (1) | AU698318B2 (de) |
| CA (1) | CA2223923A1 (de) |
| DE (1) | DE69633725T2 (de) |
| WO (1) | WO1996040962A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998052603A2 (en) * | 1997-05-23 | 1998-11-26 | Schweiz. Serum- & Impfinstitut Bern | An influenza enveloped dna vaccine |
| US5674908A (en) * | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
| US6989434B1 (en) | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
| US5830878A (en) * | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
| US20030069173A1 (en) * | 1998-03-16 | 2003-04-10 | Life Technologies, Inc. | Peptide-enhanced transfections |
| US6093816A (en) | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
| EP0941066B1 (de) * | 1996-08-26 | 2003-10-29 | Transgene S.A. | Kationische lipid-nukleinsäure komplexe |
| US7384923B2 (en) * | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
| EP0938298B1 (de) * | 1996-09-13 | 2002-12-04 | Lipoxen Technologies Limited | Liposomenzusammensetzung |
| US5958894A (en) * | 1997-04-04 | 1999-09-28 | Megabios Corporation | Amphiphilic biguanide derivatives |
| US6235310B1 (en) | 1997-04-04 | 2001-05-22 | Valentis, Inc. | Methods of delivery using cationic lipids and helper lipids |
| US6121457A (en) | 1997-11-14 | 2000-09-19 | Megabios Corporation | Compositions and methods using novel substituted imidazolium lipids |
| JP2001523480A (ja) | 1997-11-20 | 2001-11-27 | バイカル インコーポレイテッド | サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置 |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| CA2350882C (en) | 1998-11-12 | 2011-02-22 | Life Technologies Corporation | Transfection reagents |
| AUPQ259399A0 (en) | 1999-09-01 | 1999-09-23 | Lustre Investments Pte Ltd | Therapeutic agents |
| KR100373845B1 (ko) * | 2000-09-21 | 2003-02-26 | 굿젠 주식회사 | 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법 |
| US20030096414A1 (en) * | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
| US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| WO2009038779A2 (en) * | 2007-09-19 | 2009-03-26 | University Of Tennessee Research Foundation | Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents |
| US8044215B2 (en) * | 2009-04-29 | 2011-10-25 | Juvaris Biotherapeutics, Inc. | Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds |
| SI2654785T1 (sl) * | 2010-12-22 | 2019-06-28 | Bayer Intellectual Property Gmbh | Ojačan imunski odziv pri govejih vrstah |
| CA2940794C (en) | 2014-02-28 | 2022-05-31 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
| US10195280B2 (en) | 2014-07-15 | 2019-02-05 | Life Technologies Corporation | Compositions and methods for efficient delivery of molecules to cells |
| UA123265C2 (uk) * | 2015-05-04 | 2021-03-10 | Байєр Енімал Хелс Гмбх | Спосіб одержання амфіфільних сполук імідазолінію |
| CN121102495A (zh) * | 2025-11-17 | 2025-12-12 | 联合钠米(天津)科技有限公司 | 一种基于二烃基咪唑阳离子脂质的核酸药物制剂及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07503372A (ja) * | 1992-01-23 | 1995-04-13 | バイカル・インコーポレイテッド | 生体外遺伝子導入 |
| US5705655A (en) * | 1992-12-17 | 1998-01-06 | Megabios Corporation | Amphiphilic nitrogen containing imidazolinium derivative compounds and uses |
| ATE221575T1 (de) * | 1993-05-10 | 2002-08-15 | Univ Michigan | Gentransfer zu den pankreatischen epithelzellen |
| KR960705771A (ko) * | 1993-11-24 | 1996-11-08 | 벤자민 에프 맥그로우 | 구아니딘의 양쪽친화성 유도체(amphiphilic derivatives of guanidine) |
| KR960705798A (ko) * | 1993-11-24 | 1996-11-08 | 벤자민 에프 맥그로우 | 피페라진의 양쪽친화성 유도체(amphiphilic derivatives of piperazine) |
| US5830878A (en) * | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
-
1995
- 1995-06-07 US US08/485,005 patent/US5830878A/en not_active Expired - Lifetime
-
1996
- 1996-06-07 WO PCT/US1996/009526 patent/WO1996040962A1/en not_active Ceased
- 1996-06-07 AU AU61609/96A patent/AU698318B2/en not_active Expired
- 1996-06-07 DE DE69633725T patent/DE69633725T2/de not_active Expired - Lifetime
- 1996-06-07 CA CA002223923A patent/CA2223923A1/en not_active Abandoned
- 1996-06-07 EP EP96919212A patent/EP0832270B1/de not_active Expired - Lifetime
- 1996-06-07 AT AT96919212T patent/ATE280833T1/de not_active IP Right Cessation
-
1998
- 1998-11-02 US US09/184,771 patent/US6344446B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6344446B1 (en) | 2002-02-05 |
| AU6160996A (en) | 1996-12-30 |
| US5830878A (en) | 1998-11-03 |
| EP0832270A1 (de) | 1998-04-01 |
| DE69633725T2 (de) | 2005-03-17 |
| EP0832270B1 (de) | 2004-10-27 |
| AU698318B2 (en) | 1998-10-29 |
| WO1996040962A1 (en) | 1996-12-19 |
| CA2223923A1 (en) | 1996-12-19 |
| DE69633725D1 (de) | 2004-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69633725D1 (de) | Kationische lipide/dns komplexe zum zielen von genen | |
| KR960703170A (ko) | 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection) | |
| FR2712812B1 (fr) | Composition pour la production de produits thérapeutiques in vivo. | |
| CY1105475T1 (el) | Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων | |
| HUP0002454A2 (hu) | D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények | |
| TR199902529T2 (xx) | Etkinle�tirilmi� protein C form�lasyonlar�. | |
| DE69531332D1 (de) | Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert | |
| ATE411333T1 (de) | Invertierte chimäre und hybrid-oligonukleotide | |
| EP0939621A4 (de) | Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide | |
| WO1999033982A3 (en) | Human genes and gene expression products i | |
| WO1999058675A3 (en) | Human genes and gene expression products v | |
| WO1999038972A8 (en) | Human genes and gene expression products ii | |
| AU3368497A (en) | Human dnase i hyperactive variants | |
| DE60222790D1 (de) | Dendrimere zur verwendung in gezielter verabreichung | |
| RU95104940A (ru) | Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения | |
| IL141141A0 (en) | Targeting pharmaceutical agents to injured tissues | |
| FI963103A0 (fi) | Ei-virusvektori | |
| DE69709407D1 (de) | Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen | |
| PT1019040E (pt) | Inibicao da actividade de p38-quinase por meio de arilureias | |
| EP0769968A4 (de) | Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden | |
| WO2002044320A3 (en) | Human elongase genes and uses thereof | |
| WO2022256499A3 (en) | Bcma targeting trispecific proteins and methods of use | |
| WO1999064594A8 (en) | Genes and gene expression products that are differentially regulated in prostate cancer | |
| ATE345139T1 (de) | Karzinostatische wirkstoffe | |
| SE9503117D0 (sv) | Novel use of padlock probes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |